Cancer Gene Therapy Market Size, Share, and Trends 2024 to 2034

The global cancer gene therapy market size is calculated at USD 4.14 billion in 2025 and is forecasted to reach around USD 19.97 billion by 2034, accelerating at a CAGR of 19.23% from 2025 to 2034. The North America cancer gene therapy market size surpassed USD 2.13 billion in 2024 and is expanding at a CAGR of 19.24% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : January 2025
  • Report Code : 2893
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Gene Therapy Market 

5.1. COVID-19 Landscape: Cancer Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Gene Therapy Market, By Therapy

8.1. Cancer Gene Therapy Market, by Therapy

8.1.1. Gene Induced Immunotherapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Oncolytic Virotherapy

8.1.2.1. Market Revenue and Forecast

8.1.3. Gene Transfer

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Cancer Gene Therapy Market, By End-User

9.1. Cancer Gene Therapy Market, by End-User

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast

9.1.2. Biopharmaceutical Companies

9.1.2.1. Market Revenue and Forecast

9.1.3. Diagnostic centers

9.1.3.1. Market Revenue and Forecast

9.1.4. Research Institutes

9.1.4.1. Market Revenue and Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Cancer Gene Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Therapy

10.1.2. Market Revenue and Forecast, by End-User

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Therapy

10.1.3.2. Market Revenue and Forecast, by End-User

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Therapy

10.1.4.2. Market Revenue and Forecast, by End-User

10.2. Europe

10.2.1. Market Revenue and Forecast, by Therapy

10.2.2. Market Revenue and Forecast, by End-User

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Therapy

10.2.3.2. Market Revenue and Forecast, by End-User

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Therapy

10.2.4.2. Market Revenue and Forecast, by End-User

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Therapy

10.2.5.2. Market Revenue and Forecast, by End-User

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Therapy

10.2.6.2. Market Revenue and Forecast, by End-User

10.3. APAC

10.3.1. Market Revenue and Forecast, by Therapy

10.3.2. Market Revenue and Forecast, by End-User

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Therapy

10.3.3.2. Market Revenue and Forecast, by End-User

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Therapy

10.3.4.2. Market Revenue and Forecast, by End-User

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Therapy

10.3.5.2. Market Revenue and Forecast, by End-User

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Therapy

10.3.6.2. Market Revenue and Forecast, by End-User

10.4. MEA

10.4.1. Market Revenue and Forecast, by Therapy

10.4.2. Market Revenue and Forecast, by End-User

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Therapy

10.4.3.2. Market Revenue and Forecast, by End-User

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Therapy

10.4.4.2. Market Revenue and Forecast, by End-User

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Therapy

10.4.5.2. Market Revenue and Forecast, by End-User

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Therapy

10.4.6.2. Market Revenue and Forecast, by End-User

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Therapy

10.5.2. Market Revenue and Forecast, by End-User

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Therapy

10.5.3.2. Market Revenue and Forecast, by End-User

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Therapy

10.5.4.2. Market Revenue and Forecast, by End-User

Chapter 11. Company Profiles

11.1. OncoGenex Pharmaceuticals Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. MerckKGaA

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Introgen TherapeuticsInc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. GSK plc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. GenVec

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Genelux Corporation

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Elevate BioInc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. CelgeneInc

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Bluebird bio Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BioCancell Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global cancer gene therapy market size is expected to increase USD 19.97 billion by 2034 from USD 3.44 billion in 2024.

The global cancer gene therapy market will register growth rate of 19.23% between 2025 and 2034.

The major players operating in the cancer gene therapy market are OncoGenex Pharmaceuticals Inc., MerckKGaA, Introgen TherapeuticsInc, GSK plc., GenVec, Genelux Corporation, Elevate BioInc, CelgeneInc, Bluebird bio Inc., BioCancell Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Abeona Therapeutics Inc., and Others.

The driving factors of the cancer gene therapy market are the increasing demand for gene therapy and the rising incidence of cancer cases across the world.

North America region will lead the global cancer gene therapy market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client